Industry Insights · Brain–Computer Interface
Brain–spine interfaces heat up: the 'neural bridge' route and a 300M+ round
Within the broader BCI wave, the 'brain–spine interface' is becoming its own funded niche: rather than replacing function, it rebuilds the interrupted pathway between brain and spinal cord.
How it differs from a classic BCI
Classic BCIs mostly pursue 'function replacement' — decoding brain signals to drive a robotic arm, cursor or exoskeleton. A brain-spine interface pursues 'function rebuilding': reconnecting brain and cord so the patient walks with their own body.
An angel round of over RMB 300M
Founded in 2025 and spun out of Fudan University, Shenfu Jianxing announced an angel series of more than RMB 300M, led by Cathay Capital with co-leads and follow-on from existing shareholders. Proceeds target multi-center registration trials, a Pudong headquarters and global expansion.
Clinical signal and regulatory recognition
In proof-of-concept work with Fudan-affiliated Zhongshan and Huashan hospitals, several completely paralyzed spinal-cord-injury patients regained voluntary leg control within 24 hours after surgery, with hip/knee control in as little as 7 days; researchers also noted lower-limb sweating, hinting at autonomic recovery. The technology has an FDA 'Breakthrough Device' designation.
The BIO angle
FAQ
Is a brain-spine interface the same as a BCI?
It's a sub-direction of BCI. The difference: BCIs often do 'function replacement', while brain-spine interfaces do 'function rebuilding' — reconnecting brain and cord to restore the body's own movement.
What does a 'Breakthrough Device' designation mean?
An FDA program for devices that may more effectively treat serious conditions, offering closer interaction and priority review — but it is not marketing approval.
What do such implants require of materials?
Long-term implant-grade, biocompatible insulation and encapsulation, plus flexibility to limit tissue damage and foreign-body response.
Related reading
- BCI in 2026: Technology Paths, Global Landscape and China's Rise | BIO Insights
- Map of China's Core BCI Companies: Three Tiers and Technology Routes | BIO Insights
- China Prices BCI: Invasive Implantation Fee RMB 6,000–6,600 per Case | BIO Insights
Note: an original analysis compiled from public industry information; figures and conclusions per official/original sources. Not investment advice.
Building in China's medical-device market?
From advanced medical silicone/polymers to material selection, regulatory and supply, BIO helps global and local partners move from selection to landed supply in China.